Interferon-β_1b for multiple sclerosis

References Papers of special note have been highlighted as:• of interest•• of considerable interest

• Compston A, Coles A. Multiple sclerosis. Lancet 359, 1221–1231 (2002).
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice PGA et al. The natural history of multiple sclerosis: a geographically based study. Brain 112, 133–146 (1989).
   PubMed Web of Science ®Google Scholar
• O’Connor P. Key issues in the diagnosis and treatment of multiple sclerosis; an overview. Neurology 59(Suppl. 3), S1–S33 (2002).
   PubMed Web of Science ®Google Scholar
• Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116, 117–134 (1993).
   PubMed Web of Science ®Google Scholar
• Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 12, 295–302 (1999).
   PubMed Web of Science ®Google Scholar
• Bjartmar C, Kidd G, Ransohoff RM. A real-time insight into disease progression and the role of axonal injury in multiple sclerosis. Arch. Neurol. 58(1), 37–39 (2001).
   PubMedGoogle Scholar
• Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125, 2202–2212 (2002).
   PubMed Web of Science ®Google Scholar
• Hawkins SA, McDonnell GV. Bening multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J. Neurol. Neurosurg. Psychiatry 67, 148–152 (1999).
   PubMed Web of Science ®Google Scholar
• van denNoort S, Eidelman B, Rammohan K et al. National Multiple Sclerosis Society (NMSS): disease management consensus statement. National MS Society, NY, USA (1998).
   Google Scholar
• Goodin DS, Frohman EM, Garmany GP Jr et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58(2), 169–178 (2002).
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Mayr WT, McClelland RL et al. Change in MS-related disability in a population based cohort: a 10-year follow-up. Neurology 62, 51–59 (2004).
   PubMed Web of Science ®Google Scholar
• Pittock SJ, McClelland RL, Mayr WT et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann. Neurol. 56(2), 303–306 (2004).
   PubMed Web of Science ®Google Scholar
• Arnold DL, Matthews PM. MRI in the diagnosis and management of multiple sclerosis. Neurology 58(Suppl. 4), S23–S31 (2002).
   PubMed Web of Science ®Google Scholar
• Simon Jack H. Magnetic resonance imaging in the diagnosis of multiple sclerosis, elucidation of disease course, and determining prognosis. In: Multiple Sclerosis: Diagnosis, Medical Management and Rehabilitation. Burks JS, Johnson K (Eds). Demos, NY, USA, 99–126 (2004).
   Google Scholar
• Jubelt B. Post-polio syndrome. Curr. Treat. Options Neurol. 6(2), 87–93 (2000).
   Google Scholar
• Lucchinetti CF, Bruck W. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelization. Ann. Neurol. 47, 707–717 (2000).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Ford CC. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult. Scler. 9(6), 585–591 (2003).
   PubMed Web of Science ®Google Scholar
• Rice GPA, Nicolle E, Lesaux J, Ebers GC, Kremenchutzky M, Karlik S. Long term safety, compliance and evolution of neutralizing antibodies in MS patients treated with IFN-β1b. Mult. Scler. Clin. Lab. Res. 7, S54 (2001).
   Google Scholar
• Paty D. Initial symptoms. In: Multiple Sclerosis: Diagnosis, Medical Management and Rehabilitation. Burks JS, Johnson KP (Eds). Demos, NY, USA, 75–80 (2003).
   Google Scholar
• Sadovnick AD, Remick RA, Alien J et al. Depression and multiple sclerosis. Neurology 46, 628–632 (1996).
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Lucchinetti G, Rodriguez G, Weinshenker BG. Multiple Sclerosis. N. Engl. J. Med. 343(13), 938–952 (2000).
   PubMed Web of Science ®Google Scholar
• Dean G. Epidemiology of multiple sclerosis. Neuroepidemiology 3, 58–73 (1995).
   Google Scholar
• Sriram S, Stratton CW, Yao S et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Proc. Natl Acad. Sci. USA 92, 7440–7444 (1984).
   Google Scholar
• Dean G. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55(4), 458–468 (2004).
   PubMed Web of Science ®Google Scholar
• Sriram S, Stratton CW, Yao S et al. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46(4), 907–911 (1996).
   PubMed Web of Science ®Google Scholar
• Barnett MH, Prineas JW. Early onset multiple sclerosis: a longitudinal study.Neurology 59(7), 1006–1010 (2002).
   PubMed Web of Science ®Google Scholar
• McDonald W, Compston A, Edan G et al. Recommended diagnostic material for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 50, 121–127 (2001).
   PubMed Web of Science ®Google Scholar
• Bowling A. Alternative Medicine and Multiple Sclerosis. Demos, NY, USA (2004).
   Google Scholar
• Montalban X, Overview of European pilot study of IFN-β1b in primary progressive multiple sclerosis. Mult. Scler. 10(Suppl. 1), S62–S64 (2001).
   Google Scholar
• Hartung HP, Gonsette R, Konig N et al. Miloxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized multicenter trial. Lancet 360, 2018–2025 (2002).
   PubMed Web of Science ®Google Scholar
• Neuhaus O, Kieseier BC, Hartung HP. Mitoxantrone (Novantrone®) in multiple sclerosis: new insights. Neurotherapeutics 4(1), 17–26 (2004).
   Google Scholar
• Pirko I, Rodriguez M. Pulsed intravenous methylprednisolone therapy in progressive MS. Arch. Neurol. 61(7), 1148–1149 (2004).
   PubMedGoogle Scholar
• PianitchTHS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with γ IFN exacerbations associated with activation of the immune system. Neurology 37(7), 1097–1102 (1987).
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon-β1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double blind, placebo controlled trial. Neurology 43, 655–661 (1993).
   PubMed Web of Science ®Google Scholar
• Chiang J, Gloff CA, Yoshizawa N, Williams GJ. Pharmacokinetics of recombinant human interferon-β in healthy volunteers and its effect on serum neopterin. Pharmaceutical Res. 10(4), 567–572 (1993).
   PubMed Web of Science ®Google Scholar
• Witt PL. Pharmacokinetics of interferon-β and the biological markers it induces. In: Interferon Therapy of Multiple Sclerosis. RederA (Eds). M Dekker, NY, USA, 77–93 (1997).
   Google Scholar
• Williams GJ, Witt PL. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and Avonex. J. Interferon Cytokine Res. 18(11), 967–975 (1998).
   PubMed Web of Science ®Google Scholar
• Khan OA, Xia, Q, Bever Jr CT, Johnson KP, Panitch HS, Dhib-Jalbut SS. Interferon-β1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology 46, 1639–1643 (1996).
   PubMed Web of Science ®Google Scholar
• Walther EU, Hohlfeld R. Multiple sclerosis: side effects of IFN-β therapy and their management. Neurology 53, 1622–1627 (1999).
   PubMed Web of Science ®Google Scholar
• Shapiro R. Adherence to interferon β: BETA Nurse Program. Int. J. MS Care 6, 66 (2004).
   Google Scholar
• The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon-β1b is effective in relapsing remitting multiple sclerosis. Final outcome of the randomized controlled trial. Neurology 45, 1277–1285 (1995).
   PubMed Web of Science ®Google Scholar
• Paty DW, Li KKB, the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon-β1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multi-center, randomized, double-blind, placebo-controlled trial. Neurology 43, 662–667 (1993).
   PubMed Web of Science ®Google Scholar
• Petkau AJ, White RA, Ebers GC et al. Longitudinal analyses of the effects of neutralizing antibodies on IFN-β1b in relapsing-remitting multiple sclerosis. Mult. Scler. 10, 126–138 (2004).
   PubMed Web of Science ®Google Scholar
• Durelli L, Verdun E, Barbero P et al. Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every other day IFN-β1b versus once weekly IFN-β1a for multiple sclerosis. Lancet 359, 1453–1460 (2002).
   PubMed Web of Science ®Google Scholar
• Durelli L, Verdun E, Barbero P, Bergui M, Versino E; and INCOMIN Trial Study Group. Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of IFN-β products in the treatment of multiple sclerosis. Clin. Ther. 25, 105–118 (2003).
   PubMed Web of Science ®Google Scholar
• Barbero P, Verdun E, Bergui M et al. High-dose, frequently administered IFN-β therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the IFN-β dose-reduction study. J. Neurol. Sci. 222(1–2), 13–19 (2004).
   PubMed Web of Science ®Google Scholar
• Durelli L, Verdin E, Barbero P et al. Interferon ß1b in multiple sclerosis: comparing two different doses (the OPTIMS Study). Mult. Scler. 10(Suppl. 2), 603 (2004).
   Google Scholar
• European Study Group on IFN-β1b in secondary progressive MS. Placebo-controlled multi-center randomized trial of IFN-β1b in treatment of secondary progressive multiple sclerosis. Lancet 352, 1491–1497 (1998).
   PubMed Web of Science ®Google Scholar
• Molyneux L, Kappos C, Polman C et al. The effect of IFN-β1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 123, 2256–2263 (2000).
   PubMed Web of Science ®Google Scholar
• Inglese M, van Waesberghe JHTM. The effect of IFN-β1b on quantities derived from MT MRI in secondary progressive MS. Neurology 60, 853–860 (2003).
   PubMed Web of Science ®Google Scholar
• Sormani MP, Bruzzi P, Beckmann K et al. MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN-β1b. Neurology 60, 1462–1466 (2003).
   PubMed Web of Science ®Google Scholar
• Kuhle J, Hardmeier M, Rio J et al. Long-term follow-up of the European Study of Interferon-β1b (EUSPMS) in secondary progressive MS: predictors of treatment response. Mult. Scler. 10(Suppl. 2), 600 (2004).
   Google Scholar
• Freeman JA, Thompson AJ, Fitzpatrick R et al. and the European Study Group on IFN-β1b in Secondary Progressive MS: impact on quality of life. Neurology 57, 1870–1875 (2002).
   Web of Science ®Google Scholar
• Goodkin DE, and the North American Study Group on IFN-β1b in secondary progressive MS. IFN-β1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology 54, 2352 (2004).
   Google Scholar
• Shimpi A, Layton B, Bashir K. Sustained clinical effectiveness of IFN-β1b in patients with multiple sclerosis. European Neurological Society presentation (2004).
   Google Scholar
• Pachner A. Anti-IFN-β antibodies in IFN-β-treated MS patients. Neurology 61(Suppl. 5), S1–S34 (2003).
   Web of Science ®Google Scholar
• Durelli L, Ricci A. Anti IFN antibody in multiple sclerosis. Molecular basis and there impact on clinical efficacy. Frontiers Biosci. 9, 2192–2201 (2004).
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Ross C, Clemmesen KM et al. Clinical importance of neutralizing antibodies against IFN-β in patients with relapsing-remitting multiple sclerosis. Lancet 362, 1148–1191 (2003).
   Google Scholar
• Vartanian TK, Zamvil S, Fox E, Sorensen PS. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology 63(Suppl. 5), S42–S49 (2004).
   PubMed Web of Science ®Google Scholar
• Cutter G. Statistical issues in neutralizing antibodies. Neurology 61(Suppl. 5), S38–S39 (2003).
   Google Scholar
• Petkau JA. Statistical approaches to assessing the effects of neutralizing antibodies. Neurology 61(Suppl. 5), S35–S379 (1991).
   Google Scholar
• Pozzilli C, Antonini G, Bagnato F et al. Monthly corticosteroids decrease neutralizing antibodies to IFN-β1b: a randomized trial in multiple sclerosis. J. Neurol. 249, 50–56 (2003).
   Web of Science ®Google Scholar
• Hurwitz B, Polman C.H. Neutralizing Antibodies to IFN-β1b: real-world data. Mult. Scler. 9(Suppl. 1), S40 (2003).
   Google Scholar
• Coyle P. Neutralizing antibodies to IFN-β1b in the real world. Int. J. MS Care 6(2), 67 (2004).
   Google Scholar
• Hunter S. Comfort (comparative study for two high-dose IFNs in MS). Int. J. MS Care 6(2), 69 (2004).
   Google Scholar
• Harris C, Billisberger K. Injection site pain: IFN-β1b versus IFN-β1a. Int. J. MS Care 6(2), 73 (2002).
   Google Scholar
• Panitch H, Goodin DS. Randomized comparative studies of IFN-β1a treatment regimens in MS: the EVIDENCE Trial. Neurology 59, 1496–1506 (2004).
   Web of Science ®Google Scholar
• Arnason BGW. BEYOND-Betaseron® Efficacy Yielding Outcomes of a New Dose. Neurology 62(7 Suppl. 5), A490 (2004).
   Google Scholar
• Jeffery D, Arnason B, Bigley G et al. MRI outcomes in relapsing-remitting multiple sclerosis patients treated with 500 mcg IFN-β1b vs. 250 mcg every other day: first phase of the BEYOND program. Mult. Scler. 10(Suppl. 2), P589 (2004).
   PubMedGoogle Scholar
• PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group: PRISMS-4: long-term efficacy of IFN-β1a in relapsing MS. Neurology 56(12), 1628–1636 (2001).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Sandrock A. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Neurotherapeutics 4(4), 571–580 (2004).
   Google Scholar
• Cree BAC, Khan O, Bourdette D et al. Clinical characteristics of African Americans vs. Caucasian Americans with multiple sclerosis. Neurology 11(63), 2039–2045 (2004).
   Google Scholar